Gary Dahl

Clinical Trials

• Not Recruiting Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia
• Not Recruiting Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes
• Recruiting Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia
• Not Recruiting T-cell Minimal Residual Disease (MRD) Evaluation Using Flow Cytometric Analysis
• Not Recruiting A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias.
• Not Recruiting Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients
• Not Recruiting hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma
• Not Recruiting Intensive Neoadjuvant Chemotherapy in Treating Young Patients Undergoing Surgical Resection for High-Risk Hepatoblastoma
• Not Recruiting Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate
• Not Recruiting Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia
• Not Recruiting Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia
• Not Recruiting Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment
• Not Recruiting Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors
• Not Recruiting Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors